First sequential revenue gain since the commercial overhaul, up 6.3% from Q2, with full-year guidance narrowed to $142 million to $146 million and roughly $70 million in year-end cash with no debt. The loss missed expectations, keeping pressure on a $137 million market cap waiting on FDA clearance of its Alzheimer's blood test.
Quanterix Corp
QTRX at a Glance
- Market cap
- $139.1M
- Revenue (TTM)
- $148.2M
- Profit margin
- -75.0%
- EPS (TTM)
- $-2.34
- 52-week range
- $2 – $9
- Street target
- $3.33
- Next report
- Jan 6, 2027
Headquartered in Billerica, MA Fiscal year ends December NASDAQ: QTRX quanterix.com
About Quanterix
Quanterix Corporation is a precision biomarker science company.
- **Simoa research tools:** Its Simoa technology detects and quantifies protein biomarkers in blood and other fluids at ultra-low concentrations. It is offered through the HD-X, SR-X and SP-X instruments, assay kits and consumables used in neurology and other research.
- **Spatial biology:** Through the 2025 acquisition of Akoya Biosciences, Quanterix offers high-plex, single-cell spatial protein analysis in tissue. Products include the PhenoCycler Fusion and PhenoImager HT platforms, PhenoCode barcoding kits, and oncology panels such as IO60, Metabolism, TIME and ADC.
- **Accelerator Laboratory:** A fully managed service arm that supports biopharma drug trials and translational research.
- **Diagnostics:** The company is building a diagnostics business around LucentAD Complete, a five-biomarker blood test for Alzheimer's disease. The test has CMS pricing and a pending FDA 510(k). It is distributed through reference-lab partnerships in the U.S. and regional partners such as Innovita in China.
Revenue comes from product sales (instruments and consumables), services, and collaboration and license agreements. Customers are academic, government, pharma/CRO and clinical customers across the Americas, EMEA and APAC. Updated
Frequently Asked Questions
What does Quanterix do?
Quanterix Corporation is a precision biomarker science company. - **Simoa research tools:** Its Simoa technology detects and quantifies protein biomarkers in blood and other fluids at ultra-low concentrations.
What is the QTRX stock price target?
The Wall Street consensus 12-month price target for QTRX is $3.33.